- Home
- LFT vs MREO Comparison
LFT vs MREO Comparison
Compare LFT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | MREO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.1M | 49.4M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | LFT | MREO |
|---|---|---|
| Price | $1.06 | $0.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 171.0K | ★ 4.2M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 18.49% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $668.15 | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.20 |
| 52 Week High | $2.45 | $2.94 |
Technical Indicators
Market Signals| Indicator | LFT | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 48.73 |
| Support Level | $1.02 | $0.22 |
| Resistance Level | $1.40 | $0.36 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 68.75 | 33.78 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).